Axovant Sciences

CompanyBermuda

Axovant Sciences develops one asset, in phase 3, discontinued (intepirdine in Alzheimer's disease). Mostly small molecule acting on HTR6; based in Bermuda.

1
Asset
Furthest stage
Phase 3, discontinued
5
Trials
1
Signal

Pipeline

1
  • intepirdine

    Blocks serotonin 5-HT6 receptors to enhance neurotransmission involved in cognition.

    Phase 3, discontinued, Small molecule, HTR6, Alzheimer's disease, dementia with Lewy bodies (Phase 2)

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials5
  • Signals1
  • Similar companies6

Intelligence